Solid pharmaceutical preparation
AssigneeTakeda Pharmaceutical Company Limited
InventorsMasahiko Koike, Hiroyoshi Koyama, Naoru Hamaguchi
Life of this patent
Estimating the term…
Abstract
The present invention provides a solid preparation containing an insulin sensitizer and an active ingredient (except insulin sensitizers), which shows in vivo dissolution behavior of an insulin sensitizer, which is similar to the dissolution behavior of an insulin sensitizer from “a solid preparation containing an insulin sensitizer alone as an active ingredient”. The present invention provides a solid preparation containing (1) a layer containing an insulin sensitizer, and (2) a layer containing (a) an active ingredient (except insulin sensitizers), (b) microcrystalline cellulose having a mean particle size of 5-25 μm, (c) microcrystalline cellulose having a mean particle size of 30-100 μm and (d) polyvinylpyrrolidone K-90.
Claims9
A multiple-layer tablet comprising (1) a layer containing pioglitazone hydrochloride having a median size of 1 to 50 μm and (2) a layer containing (a) metformin hydrochloride having a median size of 10 to 100 μm, (b) microcrystalline cellulose having a mean particle size of 5-25 μm, (c) microcrystalline cellulose having a mean particle size of 30-100 μm and (d) polyvinylpyrrolidone K-90 in an amount of 0.1-20 parts by weight per 100 parts by weight of the multiple-layer tablet, wherein the release of metformin hydrochloride is delayed compared to release of pioglitazone hydrochloride.
A multiple-layer tablet comprising (1) a layer containing pioglitazone hydrochloride having a median size of 1 to 50 μm and (2) a layer containing (a) metformin hydrochloride having a median size of 10 to 100 μm, (b) microcrystalline cellulose having a mean particle size of 5-25 μm, (c) microcrystalline cellulose having a mean particle size of 30-100 μm and (d) polyvinylpyrrolidone K-90 in an amount of 0.1 -20 parts by weight per 100 parts by weight of the multiple-layer tablet, wherein the release of metformin hydrochloride is delayed compared to release of pioglitazone hydrochloride, and, wherein the pioglitazone hydrochloride and metformin hydrochloride show bioequivalence to administration of a first tablet comprising pioglitazone hydrochloride and a second tablet comprising metformin hydrochloride.
A multiple-layer tablet comprising (1) a layer containing pioglitazone hydrochloride having a median size of 1 to 50 μm and (2) a layer containing (a) metformin hydrochloride having a median size of 10 to 100 μm, (b) microcrystalline cellulose having a mean particle size of 5-25 μm, (c) microcrystalline cellulose having a mean particle size of 30-100 μm and (d) polyvinylpyrrolidone K-90 in an amount of 0.1-20 parts by weight per 100 parts by weight of the multiple-layer tablet, wherein the pioglitazone hydrochloride is at least about 98.5% dissolved in 30 minutes when the tablet is stirred in a hydrochloric acid-potassium chloride buffer.
A multiple-layer tablet consisting of (1) a layer containing pioglitazone hydrochloride having a median size of 1 to 50 μm and (2) a layer containing (a) metformin hydrochloride having a median size of 10 to 100 μm, (b) microcrystalline cellulose having a mean particle size of 5-25 μm, (c) microcrystalline cellulose having a mean particle size of 30-100 μm and (d) polyvinylpyrrolidone K-90 in an amount of 0.1-20 parts by weight per 100 parts by weight of the multiple-layer tablet, wherein release of metformin hydrochloride is delayed compared to release of pioglitazone hydrochloride.
Dependencies are inferred from the claim text.